Smad3 is an essential component in the intracellular signaling of transforming growth factor-b (TGFb), which is a potent inhibitor of tumor cell proliferation. BRCA2 is a tumor suppressor involved in early onset of breast, ovarian and prostate cancer. Both Smad3 and BRCA2 possess transcription activation domains. Here, we show that Smad3 and BRCA2 interact functionally and physically. We found that BRCA2 forms a complex with Smad3 in vitro and in vivo, and that both MH1 and MH2 domains of Smad3 contribute to the interaction. TGFb1 stimulates interaction of endogenous Smad3 and BRCA2 in non-transfected cells. BRCA2 co-activates Smad3-dependent transcriptional activation of luciferase reporter and expression of plasminogen activator inhibitor-1 (PAI-1). Smad3 increases the transcriptional activity of BRCA2 fused to the DNA-binding domain (DBD) of Gal4, and reciprocally, BRCA2 co-activates DBD-Gal4-Smad3. Thus, our results show that BRCA2 and Smad3 form a complex and synergize in regulation of transcription.
The receptor-activated Smad3 and Smad2 are essential components in the intracellular signaling of transforming growth factor-b (TGFb); phosphorylation of these Smads by TGFb receptors is the triggering event which induces their interaction with other proteins, nuclear translocation and initiation of transcription of target genes (Piek et al., 1999; de Caestecker et al., 2000; Miyazono et al., 2000) . Smad proteins are involved in regulation of expression of genes controlling such processes as cell cycle, apoptosis, extracellular matrix formation and differentiation. Smad inactivating mutations have been found in various human cancers; disruption of Smad signaling results in resistance of tumor cells to the growth inhibitory action of TGFb.
Thus, TGFb-specific Smads can be considered as tumor suppressors (de Caestecker et al., 2000; Miyazono et al., 2000) . As transcription factors, Smads can bind to DNA directly, e.g. Smad3 binds to the CAGA motif, or they can form complexes with other DNA-binding factors (Zawel et al., 1998; Dennler et al., 1998; Jonk et al., 1998; Vindevoghel et al., 1998; Pardali et al., 2000; Hanai et al., 1999) . Formation of complexes with other transcription factors, co-activators or co-repressors determines the effects of Smads on gene expression (Piek et al., 1999; de Caestecker et al., 2000; Miyazono et al., 2000) .
The tumor suppressor BRCA2 has been found to be mutated in human breast, ovarian and prostate cancer. BRCA2 mutations lead to a strong predisposition to hereditary breast cancer of early onset (Hofmann and Schlag, 2000; Scully and Livingston, 2000) . BRCA2 is a large protein of 384 kDa, which contains domains involved in regulation of transcriptional activity and DNA integrity. It is suggested that through interaction with p53, BRCA2 is involved in regulation of the cell cycle, while BRCA2-dependent regulation of DNA repair, in cooperation with Rad51, is involved in the maintenance of genome stability (Marmorstein et al., 1998; Milner et al., 1997; Scully and Livingston, 2000) . The nuclear localization of BRCA2 is important for its functions, as suggested by the observation that cancercausing truncations of BRCA2, which lead to deletion of its nuclear-localization signal (NLS), rendered BRCA2 inactive (Spain et al., 1999; Nordling et al., 1998) .
Interaction between various tumor suppressors and oncogenes significantly modulate their function (Hanahan and Weinberg, 2000) . Interaction between p53 and BRCA2 is an example of how one tumor suppressor can affect the functional activity of another. BRCA2 and p53 interact directly, and the formation of such a complex is important for essential cell function(s), e.g. cell proliferation. The finding that BRCA2 can inhibit the transcriptional activity of p53 suggests that BRCA2 can limit p53-dependent inhibition of cell proliferation. This is consistent with results of analysis of Brca2/p53-deficient mice, which showed milder phenotype than Brca2-deficient mice (Connor et al., 1997; Ludwig et al., 1997) . Therefore, unraveling of interacting partners of tumor suppressors can shed light on their new functions. In this study, we explored whether there is a cross-talk between tumor suppressors of two types, BRCA2 and TGFb receptor-regulated Smad3. We found that BRCA2 and Smad3 form a complex and synergize in activation of gene expression.
To investigate whether BRCA2 affects Smad function as a transcription factor, we performed an assay with the CAGA(12)-luc reporter, the activity of which can be induced in a Smad3-dependent way, as Smad3 binds directly to the CAGA element of the CAGA(12)-luc reporter (Dennler et al., 1998) . We found that transfection of BRCA2 increased Smad3-and TGFb1-induced activation of the CAGA(12)-luc reporter (Figure 1a ). This effect was dependent on the expression level of BRCA2; a high dose of BRCA2 gave the most prominent activation of the reporter upon co-transfection of Smad3. BRCA2 expression did not affect the stability of Smad3, as evaluated by immunoblotting of Smad3 in extracts of transfected cells (data not shown). We did not observe any changes in cell morphology or cell number in the experiments performed (data not shown).
To investigate whether the BRCA2 effect is dependent on a direct DNA binding of Smad3, we performed a reporter assay with Smad3 fused to Gal4 DNA-binding domain (DBD-Gal4). In this assay, Smad3 is brought to the promoter of Gal4-TK-luc reporter by DBD-Gal4, and the ability of Smad3 to bind directly DNA through its MH1 domain, does not contribute to the Smad3-dependent transcriptional activation. Thus, if the synergism of BRCA2 with Smad3 involves a modulation of the direct DNA binding of Smad3, any synergism would not be observed in this assay. However, we found that ligand-independent transcriptional activity of DBDGal4-Smad3 was enhanced by co-expression of BRCA2 ( Figure 1b ). Upon addition of TGFb1, a further slight increase of transcriptional activity was observed. This suggests that BRCA2 synergizes with Smad3 through a mechanism which does not affect the direct DNA binding of Smad3. The fact that BRCA2 synergizes with Smad3 in activation of Smad3-dependent gene expression in two different assays of transcriptional activity makes it unlikely that the effect is unspecific.
We also tested whether Smad3 can affect the transcriptional activity of BRCA2. We found that transcriptional activity of DBD-Gal4-BRCA2 was significantly increased by co-transfection of Smad3 ( Figure 1c) . Moreover, addition of TGFb1, which leads to activation of Smads, increased the transcriptional activity of DBD-Gal4-BRCA2. Since there is no specific BRCA2-inducible reporter which can be used in mammalian cells, we were unable to analyse the effect of Smad3 on the transcriptional activity of nonmodified BRCA2, i.e. without DBD-Gal4.
In order to elucidate whether the observed functional cross-talk between Smad3 and BRCA2 involves formation of a physical complex or is indirect, we performed GST-pull-down and co-immunoprecipitation assays. For the GST-pull-down assay, 3xHA-BRCA2 was expressed in 293T cells, and GST-fusion constructs of full-length and deletion mutants of (12)-luc reporter. Full-length Smad3 in pCDNA3 vector and BRCA2 in pRK5 vector (MG-B25myc) were transfected in A549 human lung carcinoma cells in indicated combinations. CAGA(12)-luc reporter was transfected in all experimental conditions. Twenty-four hours after transfection, cells were treated for the next 20 h with TGFb1 (5 ng/ml) as indicated. Luciferase activity was measured as described earlier (Yakymovych et al., 2001) . (b) BRCA2 enhances Smad3-dependent activation of Gal4-TK-luc reporter. Full-length Smad3 fused through N-terminus with DBD-Gal4 domain (DBD-Gal4-Smad3) and BRCA2 (MG-B25myc) were transfected as indicated, together with the Gal4-TK-luc reporter. (c) Smad3 enhances BRCA2-dependent activation of Gal4-TK-luc reporter. To examine transcriptional activity of BRCA2, we used the Gal4-DBD-BRCA2 exon 3 construct, described by Milner et al. (1997) . Treatment with TGFb1 and measurement of luciferase activity in assays with Gal4-TK-luc reporter (b, c) were performed as described by Yakymovych et al. (2001) . In all luciferase reporter assays, pCH110 vector expressing lacZ gene was co-transfected to normalize for transfection efficiency. Transformation doses of BRCA2 and Smad3 are shown in mg of vector DNA in 1 ml of culture medium. Values, compared by using Student's test, are marked with the following signs; #P50.01, *P50.05. Representative experiments out of 3 -5 performed, are shown Smad3 were expressed in bacteria and purified as described earlier (Yakymovych et al., 2001) . We found that BRCA2 efficiently interacted with full-length Smad3 (Figure 2) . Mutants of Smad3 with deleted MH1 or MH2 domains showed interaction with BRCA2 at 150 mM concentration of NaCl in washing buffer (data not shown), but after increase of the NaCl concentration to 500 mM, the interaction with MH1 domain-lacking mutants was significantly weaker (Figure 2a) . Further increase of NaCl concentration to 750 mM disrupted the interaction of BRCA2 with both deletion mutants, while full-length Smad3 was still able to form a complex with BRCA2 (data not shown). Similar results were obtained when full-length and deletion mutants of Smad2 were used (data not shown). These data suggest that both MH1 and MH2 domains of Smad3 and Smad2 contribute to the interaction with BRCA2 in vitro.
We next investigated whether a complex of BRCA2 and Smad3 can be formed in vivo using a coimmunoprecipitation assay. Upon overexpression in mammalian 293T cells, 6xMyc-Smad3 was co-immunoprecipitated with 3xHA-BRCA2 (Figure 3a ). This complex was formed even in the absence of treatment of cells with TGFb1, and addition of ligand did not affect Smad3-BRCA2 complex formation. The high efficiency of formation of a complex between BRCA2 and Smad3 even in the absence of ligand, is consistent with the increased ligand-independent activity of luciferase reporters upon co-expression of BRCA2 and Smad3 (Figure 1) . However, when complex formation between endogenous Smad3 and BRCA2 was investigated in non-transfected cells, we found that the complex formation was significantly enhanced upon TGFb1 treatment (Figure 3b) . The complex Smad3- BRCA2 was more abundant in a nuclear fraction then in a whole cell extract (data not shown). Thus, the interaction in the GST-pull-down assay (Figure 2 ) and the co-precipitation of Smad3 with BRCA2 (Figure 3 ), indicate that these two proteins form a physical complex.
To study whether the functional and physical interaction between BRCA2 and Smad proteins have an effect on expression of endogenous genes, we evaluated the effect of BRCA2 on TGFb/Smaddependent expression of plasminogen activator inhibitor-1 (PAI-1). PAI-1 is a direct target of Smaddependent signaling, and activation of PAI-1 reflects the potent effect of TGFb on extracellular matrix accumulation Lund et al., 1987) . Direct binding of Smad3 or Smad4 to the PAI-1 promoter has been found to be essential for stimulation of PAI-1 gene expression (Dennler et al., 1998) . To investigate whether BRCA2 affects TGFb/Smad-dependent gene expression, we performed an assay with the luciferase reporter under control of 800 bp of the natural PAI-1 promoter. We found that p800-luc reporter was stimulated by TGFb in Mv1Lu cells, and that Smad3 co-transfection significantly increased cell responsiveness to TGFb. Co-transfection of BRCA2 with Smad3 resulted in a high level of ligand-independent activation of the reporter, which was further increased upon ligand addition (Figure 4a) . Stimulation of Smad3-dependent induction of p800-luc by BRCA2 was also observed in A549 cells (data not shown). Analysis of expression of endogenous PAI-1 protein showed that BRCA2 transfection potentiated TGFb-dependent induction of PAI-1 expression in Mv1Lu cells (Figure 4b ), albeit less pronounced than induction of p800-luc reporter. This potentiation was even stronger than upon transfection of Smad3. The highest level of PAI-1 induction upon TGFb treatment was observed upon co-transfection of both BRCA2 and Smad3 (Figure 4b) . Thus, the results of these two assays, natural promoter-containing reporter and PAI-1 expression assays, show that cooperation between BRCA2 and Smad3 also affects expression of an endogenous gene.
In this study, we show that BRCA2 is a Smadinteracting protein which synergizes with Smad3 in transcriptional regulation. Other interacting proteins have also been shown to modulate the transcriptional activity of Smad3. This modulation can enhance the effects of Smads, as has been shown for FAST1 (Chen et al., 1996) , Sp1 (Moustakas and Kardassis, 1998), AP-1 (Zhang et al., 1998; Liberati et al., 1999) , or TFE3 (Hua et al., 1998) . It can also repress Smad activity, as has been shown for Ski/Sno (Akiyoshi et al., 1999; Stroschein et al., 1999; Sun et al., 1999) , or Evi1 (Kurokawa et al., 1998) . Understanding of the detailed molecular mechanism of the cross-talk between Smad3 and BRCA2 needs further studies. It is possible that the Smad3-BRCA2 complex contains additional components. One such candidate is P/CAF, since Fuks et al. (1998) have showed that BRCA2 interacts with P/CAF, and Itoh et al. (2000) have showed that also Smad3 forms a complex with P/CAF. It will also be important to evaluate in future studies whether BRCA2-Smad3 interaction changes preferences of target genes, compared to the action of Smad3 or BRCA2 alone.
Our data show a cross-talk between two tumor suppressors, i.e. TGFb-regulated Smad3 and BRCA2, Figure 4 BRCA2 synergize with Smad3 in activation of PAI-1 expression. (a) Mv1Lu cells were transfected with p800-luc reporter in combinations with myc-Smad3 in pCDNA3 vector and BRCA2 (MG-B25myc) essentially as described by Yakymovych et al. (2001) , and treated with TGFb1 (5 ng/ml) as indicated. After 20 h, luciferase activity was measured and normalized to b-galactosidase expression as in Figure 1 . Cells transfected with myc-Smad3 compared to cells transfected with myc-Smad3 and BRCA2 without TGFb1 treatment (*P50.01). (b) Mv1Lu cells were transfected with BRCA2 and Smad3 as indicated, and treated or not with TGFb1 (10 ng/ml) for 3 h to induce PAI-1 expression. Endogenous PAI-1 was extracted from extracellular matrix of 35 S-labeled cells (30 mCi/ml, 3 h), and resolved by SDS -PAGE, as described by Laiho et al. (1987) . PAI-1 was identified as a characteristic protein migrating in the 45 kDa region. Incorporation of 35 S radioactivity in PAI-1 bands is shown in arbitrary units. A representative experiment out of three performed, is shown and suggest that deletion of one of the proteins may cause functional inhibition of the other. This may be of importance for an evaluation of screening results for prognostic clinical markers. Notably, an inactivation of BRCA2 may affect the TGFb/Smad3-dependent signaling, and therefore promote the release of cells from the growth inhibitory action of TGFb. This possibility is currently under investigation.
